Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 21, 2025 08:30 ET | Source: Stemline Therapeutics, Inc.

Tempus and Stemline Therapeutics, Inc., A Subsidiary of the Menarini Group, Announce Collaboration to Implement Tempus Next, an AI-Enabled Care Pathway Intelligence Platform to Support Patients with Metastatic Breast Cancer

Up to 50% of patients with ER+/HER2- mBC could develop ESR1 mutations as a result of prior exposure to endocrine therapy in the metastatic setting. Testing to identify these mutations can help...
October 21, 2024 07:00 ET | Source: Avacta Group

Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology

Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology LONDON – Oct. 21, 2024 – Avacta...

Search Results